Tesamorelin 10mg

Tesamorelin 10 mg is a synthetic peptide research compound supplied by Grail Formula for scientific investigation and controlled laboratory experimentation involving growth hormone-releasing hormone receptor signalling, endocrine regulatory pathways and peptide-mediated cellular communication.

For research use only — not for human or veterinary use.

 

Product Overview

Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH), investigated in scientific research involving hypothalamic-pituitary signalling, growth hormone-related regulatory mechanisms and receptor-mediated intracellular responses.

Its defined peptide structure and relationship to naturally occurring GHRH make it relevant to laboratory investigations examining the molecular mechanisms through which peptide ligands interact with endocrine regulatory systems.

Grail Formula supplies Tesamorelin 10 mg as a nominal 10 mg peptide research preparation intended for controlled scientific experimentation and analytical laboratory studies.

Independent third-party analysis was conducted by Liquilabs s.r.o., Czechia. The Certificate of Analysis, published on 11 October 2026, identifies production batch GF-TESA10-B242 and reports a measured assay content of 8.66 mg with chromatographic purity of 98.6 %.

The measured assay content is 1.34 mg below the nominal 10 mg designation, corresponding to a 13.4 % shortfall. This difference is disclosed separately from the reported chromatographic purity.

The Certificate of Analysis also reports a measurable total aerobic microbial count of 50 CFU/g. This result is within the laboratory’s stated acceptable range but must not be interpreted as an absence of microbial growth.

Chromatographic purity, measured peptide quantity and microbiological findings represent distinct analytical characteristics. High chromatographic purity does not establish that the nominal quantity is present or that a preparation is sterile or suitable for administration.

 

Peptide Overview

Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone, a hypothalamic regulatory peptide involved in communication with the anterior pituitary.

GHRH interacts with the growth hormone-releasing hormone receptor (GHRHR), a G protein-coupled receptor associated with intracellular signalling pathways that contribute to the regulation of growth hormone secretion.

Tesamorelin is structurally related to human GHRH and incorporates a modification intended to influence the properties of the peptide compared with the naturally occurring sequence.

Its molecular structure makes it relevant to investigations involving peptide-receptor recognition, ligand stability, intracellular signalling and endocrine feedback mechanisms.

Research into GHRH analogues examines how changes in peptide structure may influence receptor interactions, molecular stability and experimentally observed biological responses.

Tesamorelin has also been investigated in scientific studies involving growth hormone-associated metabolic regulation and downstream endocrine signalling systems.

However, biological responses depend on the experimental model, cellular environment and measurement methods employed. Findings from clinical research involving regulated pharmaceutical formulations cannot be assumed to apply to this Grail Formula laboratory research preparation.

The material described here is intended exclusively for scientific laboratory and in vitro research, not for human or veterinary applications.

 

Historical Background and Scientific Context

Scientific understanding of growth hormone regulation developed through investigations into the hypothalamus, pituitary gland and the endocrine feedback mechanisms that coordinate hormonal signalling.

During the twentieth century, researchers identified hypothalamic factors involved in regulating pituitary hormone secretion, establishing the foundation for later investigations into growth hormone-releasing hormone.

The identification and characterisation of GHRH contributed to understanding how peptide signals originating in the hypothalamus interact with receptors in the anterior pituitary.

Subsequent advances in peptide synthesis allowed researchers to develop synthetic analogues with defined structural modifications and investigate their molecular characteristics.

Tesamorelin emerged from this broader field of GHRH analogue research, in which investigators examined peptide stability, receptor-associated signalling and growth hormone-related regulatory processes.

Research involving Tesamorelin has included investigations into endocrine physiology, metabolic regulation and the biological consequences of GHRH receptor activation.

Some pharmaceutical formulations containing Tesamorelin have been evaluated in clinical development programmes and authorised for specific uses in certain jurisdictions. Such authorisation is formulation-specific and does not establish equivalent regulatory status for research-grade preparations.

Modern analytical chemistry has also improved the characterisation of synthetic GHRH analogues through chromatographic separation, quantitative assay procedures and mass spectrometric identity assessment.

These techniques allow researchers to distinguish between peptide identity, chromatographic purity and the actual measured quantity of a compound within a tested preparation.

Continued laboratory research into Tesamorelin contributes to broader scientific investigations of GHRH receptor biology, intracellular signalling and peptide structure-function relationships.

 

Mechanistic Focus in Research

The primary mechanistic focus of Tesamorelin research concerns its interaction with the growth hormone-releasing hormone receptor, a G protein-coupled receptor involved in endocrine regulatory signalling.

GHRH receptor-associated signalling

GHRH receptor activation is associated with Gs protein-mediated signalling and the stimulation of adenylyl cyclase, an enzyme involved in the production of cyclic adenosine monophosphate (cAMP).

In experimental systems, increased intracellular cAMP can contribute to the activation of protein kinase A and downstream signalling mechanisms involved in cellular regulatory responses.

Researchers investigate these pathways to understand how peptide-receptor interactions influence intracellular communication and endocrine-related signalling processes.

Hypothalamic-pituitary regulatory pathways

Tesamorelin is relevant to investigations involving the molecular relationship between hypothalamic peptide signals and pituitary receptor systems.

Experimental research may examine receptor expression, cellular responsiveness and feedback-associated signalling under defined laboratory conditions.

These investigations contribute to understanding the regulatory complexity of growth hormone-associated biological systems.

Peptide structure and receptor recognition

The structural relationship between Tesamorelin and endogenous GHRH provides a basis for studying peptide modifications and their influence on receptor interactions.

Researchers may investigate ligand recognition, molecular stability and structure-activity relationships using suitable analytical and experimental models.

Downstream cellular signalling

GHRH receptor-associated pathways have been studied in connection with intracellular signalling mechanisms that contribute to broader endocrine regulation.

Laboratory investigations may examine changes in signalling intermediates, receptor-mediated responses and experimentally measured cellular activity.

However, the supplied Certificate of Analysis does not contain biological activity assays demonstrating receptor activation, growth hormone release or downstream functional effects for this particular batch.

Mechanistic descriptions therefore reflect established scientific research areas associated with Tesamorelin and GHRH receptor biology rather than independently demonstrated biological properties of the tested preparation.

 

Analytical Verification (COA)

Grail Formula supports batch-specific analytical transparency through independent third-party laboratory testing. The Tesamorelin 10 mg Certificate of Analysis was issued by Liquilabs s.r.o., Czechia, with a publication date of 11 October 2026.

The report identifies sample LYO-1010, batch GF-TESA10-B242, and documents peptide assay content, chromatographic purity, identity assessment, microbiological counts, bacterial endotoxins and elemental impurities.

Peptide assay and chromatographic purity

• Nominal product quantity: 10 mg
• Measured Tesamorelin assay content: 8.66 mg ± 0.04 mg
• Reported Tesamorelin purity: 98.6 % ± 0.5 percentage points
• Measured assay difference from nominal quantity: 1.34 mg below the labelled 10 mg
• Measured assay as a proportion of nominal quantity: 86.6 %
• Peptide analysis designation: Peptide Screening 0.1% TFA

The measured assay content represents a 13.4 % shortfall relative to the nominal 10 mg quantity. This is an important batch-specific analytical discrepancy and is disclosed independently of the purity result.

The reported chromatographic purity of 98.6 % describes the relative composition observed under the applied analytical conditions. It does not indicate that 98.6 % of the nominal 10 mg quantity was recovered.

Peptide identity assessment

• Spectrum identification result: 964 ± 5, as reported
• Retention time identification result: 0.998 ± 0.005, as reported
• Molecular ion mass identification: 5135 Da ± 1 Da
• Mass spectrometry identity assessment: MS deconvolution

The Certificate of Analysis includes chromatographic records and mass spectrometric documentation supporting the analytical characterisation of the tested peptide.

The spectrum identification and retention time values are reproduced as reported. The COA does not explicitly identify the spectrum measurement as FTIR or provide separate pass/fail interpretations for these identification values.

Bacterial endotoxin and microbiological assessment

• Bacterial endotoxin: 0.010 EU/mg
• Reported endotoxin acceptable range: 0–0.5 EU/mg
• Total aerobic microbial count: 5 × 10¹ CFU/g (50 CFU/g), reported uncertainty ± 2
• Total yeast and mould count: 0 CFU/g
• Reported aerobic microbial count range: 0–1000 CFU/g
• Reported yeast and mould count range: 0–100 CFU/g

Microbiological testing references USP <61> / European Pharmacopoeia 2.6.12 plate-count methodology. Bacterial endotoxin determination references USP <85> / European Pharmacopoeia 2.6.14 chromogenic testing.

The total aerobic microbial count of 50 CFU/g indicates measurable microbial growth under the applied testing conditions. Although the result falls within the laboratory’s stated acceptable range, it must not be represented as a zero microbial count.

The total yeast and mould count was reported as 0 CFU/g. Bacterial endotoxin was measured at 0.010 EU/mg, within the laboratory’s stated acceptable range.

These findings describe the tested sample and do not establish sterility, biological safety or suitability for administration.

Elemental impurity screening

Seven elemental impurities were evaluated using screening procedures referenced to USP <232> and European Pharmacopoeia 5.20 / 2.4.20.

• Arsenic: below 0.001 ppm
• Cadmium: below 0.001 ppm
• Mercury (listed as quicksilver): below 0.001 ppm
• Lead: below 0.001 ppm
• Nickel: below 0.001 ppm
• Vanadium: below 0.001 ppm
• Cobalt: below 0.001 ppm

All seven reported elemental impurity results were below 0.001 ppm and within their respective stated acceptable ranges.

Results below the analytical reporting threshold indicate concentrations below the specified level rather than confirmation of absolute absence.

The complete 13-page Certificate of Analysis contains analytical method specifications, chromatographic documentation, mass spectrometric records, endotoxin determination information and microbiological methodology descriptions.

 

Research Applications

Tesamorelin is investigated in experimental peptide biology, endocrine signalling and receptor-mediated cellular research. Its relevance arises from its structural relationship to GHRH and its association with growth hormone-releasing hormone receptor pathways.

Potential areas of laboratory investigation include:

• Growth hormone-releasing hormone receptor signalling
• Hypothalamic-pituitary regulatory pathway research
• G protein-coupled receptor activation mechanisms
• Intracellular cAMP and protein kinase A signalling
• Peptide structure-activity relationships
• Experimental endocrine feedback regulation
• Receptor-ligand recognition and molecular interaction studies
• Analytical peptide identity and purity characterisation

These applications represent scientific research directions rather than demonstrated therapeutic benefits. Individual experiments require suitable controls, validated measurement endpoints and careful interpretation of results.

Batch-specific analytical documentation can support laboratory recordkeeping and assist researchers in evaluating the reported characteristics of the tested preparation.

 

Grail Formula Quality

Grail Formula focuses on supplying laboratory research compounds supported by transparent product information and independently documented analytical findings.

For Tesamorelin 10 mg, independent Liquilabs testing provides measured information concerning peptide assay content, chromatographic purity, analytical identity, bacterial endotoxin levels, microbiological counts and selected elemental impurities.

The report documents a measured assay content of 8.66 mg against the nominal 10 mg quantity and a total aerobic microbial count of 50 CFU/g. These results are disclosed as part of the batch-specific analytical profile.

Each finding should be interpreted within the scope of the tested sample, the applied analytical methodology and the reported measurement uncertainty.

Transparent reporting of both favourable results and analytical discrepancies supports informed laboratory assessment and appropriate research documentation.

 

When You Choose Grail Formula

Choosing Grail Formula means selecting a research compound accompanied by independently documented, batch-specific analytical information rather than relying solely on general product specifications.

For this Tesamorelin preparation, researchers can review the Liquilabs Certificate of Analysis to examine the reported purity, measured peptide content, identity assessment, microbiological findings and elemental impurity screening.

The report provides a defined batch reference and publication date, allowing the analytical findings to be associated with the identified production batch.

Grail Formula emphasises factual product presentation, research-oriented documentation and transparent reporting of analytical results, including the measured assay shortfall and detectable aerobic microbial count.

 

Research Use Limitation

• Used solely for laboratory and in vitro research
• Not approved for human consumption
• Not approved for veterinary use
• Not intended for diagnostic purposes
• Not intended for therapeutic applications
• Not permitted for clinical administration
• For research use only

• Independently analysed by Liquilabs s.r.o. Czechia
• Tesamorelin purity: 98.6 % reported by COA
• Assay content measured at 8.66 mg against a nominal 10 mg
• Measured assay shortfall of 1.34 mg (13.4 % below nominal quantity)
• Identification evaluated by spectrum and retention time analysis
• Molecular ion mass identified at 5135 Da
• Bacterial endotoxin level of 0.010 EU/mg
• Total aerobic microbial count: 50 CFU/g
• Total yeast and mould count: 0 CFU/g
• All seven reported elemental impurities below 0.001 ppm
• Batch number: GF-TESA10-B242
• COA publication date: 11 October 2026
• Complete batch-specific COA traceability
• Synthetic GHRH analogue for endocrine signalling and receptor research
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.